Clinical Research

Banner ASC in Sun City, Arizona.

PAD patients fare better when they have a strong support system

PAD patients with a strong social support system were associated with better outcomes in a new analysis published in the Journal of Vascular Surgery.

Heart attack patients see no benefits from stopping long-term beta-blocker therapy

Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

Thumbnail

Both diabetes and prediabetes accelerate brain aging, MRI analysis shows

The less control a person has over their diabetes, the greater the difference between chronological age and estimated brain age based on MRI markers, according to the study. 

ESC Congress 2023 in Amsterdam

AI for TAVR, robot-guided echo and more: Key research at ESC Congress 2024

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different. 

TCT 2023 crowd

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

New PET technique improves imaging of pediatric neuroblastoma.

New PET technique slashes scan times, improves image quality in neuroblastoma cases

The method also reduces radiation doses and eliminates the need for sedation or general anesthesia.

Thumbnail

Odds of late-stage cancer diagnosis double when women put off annual breast cancer screening

Biennial and intermittent screening also significantly decrease rates of overall survival, a new analysis shows.

cardiologist viewing heart data

TAVR and SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Researchers combined data from three well-known clinical trials—NOTION, Evolut Low Risk and PARTNER 3—and evaluated thousands of low-risk patients who presented with severe aortic stenosis.